Article history: Received 26 January 2017 Accepted 10 February 2017 Available online xxxx Aim: Characterize pharmacokinetics, pharmacodynamics, and safety/tolerability of USL261 in geriatric adults to inform its potential for treating bouts of increased seizure activity. Methods: Phase 1, randomized, double-blind, 2-way crossover study in healthy geriatric (≥65 years; n = 18) and non-geriatric (18-40 years; n = 12) adults evaluated single USL261 doses (2.5 and 5.0 mg) administered intranasally. Pharmacokinetic parameters were estimated for midazolam and 1-hydroxymidazolam (active metabolite), including area under the plasma concentration-time curve (AUC), maximum plasma concentration (C max ), time to C max (T max ), and half-life (t 1/2 ). Stanford Sleepiness Scale and Observer's Assessment of Alertness/ Sedation assessed sedation; Digit-Symbol Substitution Test assessed psychomotor performance. Results: Midazolam exposure and plasma concentrations were higher in geriatric versus non-geriatric adults (geometric mean AUC 0-∞ [ng*h/mL] 2.5 mg: 70 vs 54, respectively; 5.0 mg: 157 vs 110; C max [ng/mL] 2.5 mg: 27.1 vs 22.5; 5.0 mg: 55.8 vs 46.1). USL261 was rapidly absorbed, with no differences in median T max (14.5-17.3 min); mean t 1/2 was longer in geriatric subjects. Similar age-related trends were observed for 1-hydroxymidazolam. Mean maximum observed pharmacodynamic effects were not significantly different between age groups, though were more pronounced following 5.0 versus 2.5 mg (P b .05); return to baseline was generally achieved within 4 h. USL261 was generally well tolerated, with similar adverse event rates between age groups. Conclusions: Despite increased midazolam exposure in geriatric subjects, there were no differences between age groups in pharmacodynamic effects or adverse event rates. USL261 was rapidly absorbed and pharmacodynamic effects returned to baseline within~4 h, regardless of age. Dose-dependent pharmacokinetic and maximum pharmacodynamic effects were observed. Overall, pharmacokinetic findings for USL261 were similar to studies evaluating intravenous midazolam, whereas pharmacodynamic effects were less pronounced in the elderly than previously reported.
Introduction
Seizure clusters and prolonged seizures may result in brain injury, and are associated with increased morbidity, mortality, and risk of status epilepticus [1, 2] ; interventions that can quickly interrupt seizure progression are essential. Benzodiazepines-central nervous system depressants that modulate GABA A receptor activity [3] -are often administered intravenously (IV) for rapid cessation of acute seizures [4, 5] . Intravenous administration requires skilled personnel, so treatment may not always be possible; therefore, benzodiazepines that can be administered at home fill an unmet patient need.
Rectal diazepam (DZP) is approved by the United States (U.S.) Food and Drug Administration as outpatient treatment for patients with bouts of increased seizure activity [6] . Although the rectum an effective delivery route, caregivers express desires for alternative, more socially satisfactory treatment options [7] [8] [9] [10] [11] . Buccal midazolam (MDZ) is approved in the European Union for the treatment of prolonged, acute, convulsive seizures in pediatric patients aged 3 months to b 18 years [12] . In the U.S., MDZ is indicated for many non-seizure-related uses, including IV and oral administration during procedural sedation and anesthesia induction. Though not approved in the US as rescue treatment for seizures, several studies have found MDZ to be efficacious for the cessation of seizures in both children and adults [1, [13] [14] [15] [16] . A common route of administration studied has been intranasal (IN), which includes use of a mucosal atomization device [10, 17] or needleless syringe to drip MDZ IV solution into nostrils [7, 9, 11, 18, 19] . However, IV MDZ is not optimized for IN use, and may necessitate large administration volumes [20, 21] .
Intranasal delivery of MDZ results in rapid absorption and largely avoids first-pass metabolism by cytochrome P450 (CYP) 3A in the liver [22] and small intestine [23] . This results in decreased production of the main metabolite 1-hydroxymidazolam (1-OH-MDZ), similar to that seen with IV administration [24] [25] [26] [27] . Though 1-OH-MDZ is pharmacologically active and equipotent to MDZ [28, 29] , it is rapidly inactivated through glucuronidation [30] . In contrast, oral MDZ is subject to first-pass metabolism, decreasing its absolute bioavailability to 40-50% [14, 31] .
USL261, a single-dose nasal spray formulation of MDZ optimized with an appropriate volume for IN delivery, is being investigated as a treatment for patients who require control of intermittent bouts of increased seizure activity. A phase 1 study in healthy adults comparing pharmacokinetics (PK) and pharmacodynamics (PD) of a pilot formulation of USL261 to the IV MDZ formulation administered IV or IN showed that USL261 provided rapid delivery of MDZ, with increased absorption compared with IN administration of IV solution [32] . A phase 1 PK/PD study of USL261 2.5, 5.0, and 7.5 mg in patients with epilepsy showed MDZ exposure increased with ascending doses and PD effects returned to near baseline values within 4 h [33, 34] . Both studies showed USL261 was well tolerated up to 7.5 mg. A third phase 1 study found USL261 was well tolerated up to 20 mg [35] . Three Phase 3 clinical trials evaluating efficacy and safety of USL261 in patients with epilepsy are ongoing (clinicaltrials.gov: NCT01390220, NCT01529034, NCT01999777).
As drug metabolism and drug sensitivity generally change with increasing age [36, 37] , it is necessary to evaluate drug pharmacology in the elderly to ensure safe and effective use [38] . However, PK and PD findings of non-nasal MDZ formulations have been inconsistent across studies. For example, while some studies have shown PK and PD differences between elderly and young adults [39] [40] [41] [42] [43] , others have shown no differences [44] [45] [46] . Possible explanations for these conflicting results include variability in routes of administration and techniques, dosage, comorbidities, and normal age-related physiological processes related to absorption, distribution, metabolism, and excretion [36, 37] .
The purpose of this study was to evaluate the PK, PD, and safety/ tolerability of two clinically relevant doses of USL261 in healthy geriatric and non-geriatric subjects.
Methods

Study design
A randomized, double-blind, single-dose, single-center, phase 1 crossover study was conducted to evaluate the effects of 2.5 mg and 5.0 mg USL261 administered intranasally in healthy geriatric and nongeriatric adults. Treatment periods were separated with a 4-to 10-day washout. For each study period, subjects were housed at the clinical research unit from~10 h before dosing until after the 24-h blood draw.
The study was performed in accordance with the ethical principles set forth in the Declaration of Helsinki. All pertinent study documents were reviewed by the Chesapeake Research Review, Inc. Institutional Review Board prior to study initiation (reference number Pro00009179). Subjects provided written informed consent prior to study procedures.
Subjects
Eligible patients were healthy male and female adults aged 18-40 years of age, inclusive (non-geriatric), or ≥65 years (geriatric) with a body mass index of 18-32 kg/m 2 . Subjects with MDZ allergies, acute or chronic nasal symptoms, nasal polyps, deviated septum, intolerance to intranasal administration or other nasal physical abnormalities were excluded. Additional reasons for exclusion included clinically significant medical conditions, alcohol/psychoactive substance use disorder in past 2 years, cardiac conduction defects, or neurological disorders. Subjects who used medications, vaccines, or supplements that might affect MDZ metabolism or nasal physiology within 14 days prior to study-drug administration were also excluded.
Pharmacokinetic (PK) measures
Blood samples were collected pre-dose and at 5, 10, 15, 20, 25, 30, 45, 60, 90 min, and 2, 4, 6, 8, 12, 16 , and 24 h post-dose. Plasma concentrations of MDZ and 1-OH-MDZ were determined using a validated liquid chromatography tandem mass spectrometry method with a bias of 2.9% and precision of 8.5% at the lower limit of quantitation of 0.1 ng/mL for both analytes. No assay interference was observed with paracetamol, acetylsalicylic acid, caffeine, dextromethorphan, dimenhydrinate, diphenhydramine, ibuprofen, nicotine, pseudoephedrine, cotinine, ethinyl estradiol, levonorgestrel or salicylic acid.
Pharmacodynamic (PD) evaluations
Sedation was assessed using 2 validated instruments: the selfreported Stanford Sleepiness Scale (SSS) [47] and the clinician-rated Observer's Assessment of Alertness/Sedation Scale (OAA/S) [48] . The SSS is a 1-item test used to evaluate sleepiness at specific moments in time. Subjects select 1 of 7 statements best representing their sleepiness level, with higher values for increasing levels of sedation (1 = wide awake; 7 = sleep onset soon). For sleeping subjects, "7" was assigned. The OAA/S utilizes a qualitative categorical measure to rate sedation. Lower scores signify increasing sedation for all four categories: responsiveness, speech, facial expression, and eyes. OAA/S can be assessed Psychomotor impairment was assessed using the paper-based DigitSymbol Substitution Test (DSST), which measures associative ability and performance based on a digit-symbol code (each of 9 digits is paired with a different symbol) [49] . The DSST Completion Rate = number of trials attempted/90 s; DSST percent correct score = number of correct trials in 90 s/number trials attempted * 100. The DSST assessments were performed at initial screening, check-in, pre-dose and at 10, 20, 30, 45, 60, 90 min, and 2, 3, 4, 6, 8, and 12 h post-dose. To account for learning effects, different digit/symbol combinations were used at each time point. The DSST scores were baseline-adjusted due to the lower values for geriatric subjects, which is consistent with agenormative data for the DSST [50] .
Safety and tolerability assessments
Treatment-emergent adverse events (TEAEs) were coded with the Medical Dictionary for Regulatory Activities (MedDRA®), Version 16.1 and summarized by dose, severity, and relationship to treatment for each age group. Safety was assessed through laboratory values (serum chemistry, hematology, and urinalysis), vital signs (including blood pressure, heart rate, and respiration), continuous pulse oximetry monitoring, electrocardiogram, examinations (physical, neurological, nasal), and the Columbia Suicidality Severity Rating Scale.
Study populations and statistical analyses
Assuming a between-subject coefficient of variation of 35% and 50% for non-geriatric and geriatric subjects, respectively, and a maximum dropout rate of 25%, a target population of 12 non-geriatric and 18 geriatric patients was selected to provide sufficient precision in the estimates of clearance and volume of distribution [51] .
Demographics, baseline characteristics, and safety/tolerability analyses were based on the safety population (all subjects with ≥ 1 dose of study drug). The PK and PD populations included all subjects who received ≥1 dose of study drug and for whom sufficient samples or scores, respectively, were collected for accuracy.
PK analyses
The following PK parameters were calculated with noncompartmental methods using Phoenix® WinNonlin®, Version 6.3 (Pharsight Corporation, Princeton, NJ) and SAS®, Version 9.3 (SAS, Cary, NC): area under the plasma concentration-time curve estimated from 0 to infinity (AUC 0-∞ ), maximum plasma concentration (C max ), time to C max (T max ), half-life (t 1/2 ), AUC 0-∞ for MDZ + 1-OH-MDZ, apparent total body clearance (CL/F), apparent volume of distribution (Vz/F), and metabolite-to-parent molar ratio (MR) for AUC 0-∞ and C max . Plasma concentrations below the limit of quantitation after the first quantifiable concentration were treated as missing. Statistical analyses were performed to compare differences in PK parameters between treatments (2.5 and 5.0 mg USL261) and populations (geriatric and non-geriatric). Analysis of variance (ANOVA) with fixed effects (sequence, period, age group, treatment, and age group * treatment interaction) and random effects (subject) were performed on natural log-transformed AUC 0-∞ and C max data to obtain geometric leastsquares mean (GLSM) values. The GLSM ratios and 90% confidence intervals (CI) were expressed as a percentage relative to reference treatment (5.0 mg USL261) or age group (non-geriatric subjects). All statistics were calculated using SAS®, Version 9.3. Dose proportionality was evaluated using an ANOVA model including fixed effects (period, sequence, and treatment) and random effect (participant within sequence). Data from 2.5 mg was dose-normalized to a 5.0 mg dose. Dose proportionality was declared if 90% CI for the ratio of natural log-transformed and dose-normalized AUC 0-∞ and C max values for 2.5 mg and 5.0 mg fell within the standard 80%-125% interval.
PD analyses
Changes from baseline for the DSST were summarized using descriptive statistics. The following PD parameters were calculated: maximum observed PD effect (E max ) and time to peak effect (T effect ). For comparison between age groups and dose levels, an ANOVA was utilized as described for PK parameters. E max variables were natural log-transformed prior to statistical modeling (assuming the underlying statistical distribution was similar to C max of PK parameters) using the SAS® procedure PROC MIXED.
Results
Subject disposition and demographics
All 30 subjects randomized to treatment completed the study (geriatric n = 18; non-geriatric n = 12). Of the 18 geriatric subjects, three were ≥ 75 years old. Weight and sex were similar between age groups, whereas non-geriatric subjects displayed more racial and ethnic variation (Table 1) .
Pharmacokinetics
Higher mean plasma MDZ concentrations were observed in geriatric subjects following a single 5.0 mg USL261 dose (Fig. 1) .
AUC 0-∞ was higher in geriatric subjects compared with non-geriatric subjects at both dose levels ( Fig. 2; Table 2 ). When comparing GLSM values, AUC 0-∞ was 30% and 45% higher in geriatric versus nongeriatric subjects at the 5 mg and 2.5 mg doses, respectively (Table 2) , with the 90% CI outside the standard 80%-125% equivalence interval. Similar trends were observed for maximum plasma concentration (C max ), with approximately 20% higher GLSM C max values in geriatric subjects following both doses ( Fig. 2 ; Table 2 ).
Despite higher peak concentrations, T max was similar across both USL261 doses and age groups (14.5-17.3 min), indicating that MDZ is rapidly absorbed following USL261 administration ( Table 2 ). The CL/F of MDZ was lower in geriatric subjects across both doses (Table 2) , and changes in apparent clearance resulted in a longer mean t 1/2 in the geriatric versus non-geriatric group (~8 h vs~6 h, respectively). V z /F was similar between age groups at both dose levels ( Table 2) . Across all subjects, AUC 0-∞ and C max of MDZ increased proportionally to dose, as 90% CI of GLSM ratios of dose-normalized 2.5 mg to 5 mg fell between 80 and 125% (supplemental Table 1 ).
Trends in the PK of MDZ and 1-OH-MDZ were similar, with increased exposure in the geriatric group and greater AUC and C max values following 5.0 mg USL261 (Table 2 ). T max for 1-OH-MDZ was~1 h, regardless of dose or age; t 1/2 for 1-OH-MDZ was longer for geriatric subjects at the lower dose, but was similar for both groups at the higher dose. Similarly, geometric means for the combined AUC 0-∞ of MDZ and 1-OH-MDZ (expressed as MDZ equivalents) were higher in geriatric subjects. Metabolite-to-parent MR were similar across doses and groups (~0.17 and 0.085 for AUC 0-∞ and C max , respectively; Table 2 ).
Pharmacodynamics
Sedation: Stanford Sleepiness Scale
Subjects rapidly reported sedation following 2.5 mg or 5.0 mg USL261 (Fig. 3A) , with median T effect ranging from 14 to 52 min; the overall effect lasted~4 h (Fig. 3A) . Three subjects (n = 1 geriatric; n = 2 non-geriatric) receiving the 5.0 mg dose fell asleep and did not complete the assessment at 1 to 3 time points. For both age groups, E max was 26-31% lower following 2.5 mg versus 5.0 mg (P b 0.01), indicating a significant dose-response (Fig. 3B, supplemental Table 2 ). In contrast, age did not significantly impact SSS E max scores (percent mean ratios were close to 100% for both 2.5 and 5.0 mg doses; supplemental Table 2 ). However, as mean baseline SSS scores were higher in non-geriatric subjects, the lack of age-related differences may not adequately reflect differences between age groups.
Sedation: Observer's Assessment of Alertness/Sedation Scale
Results from OAA/S sum score were in alignment with those from SSS, with peak sedation observed within 15-30 min (Fig. 3C ). Median T effect values for OAA/S sum scores were slightly faster in geriatric (14 min for both doses) versus non-geriatric subjects (22 min for 2.5 mg and 29 min for 5.0 mg). Sedation was transient, with return to baseline values by~4 h post-dose for most subjects, though judged graphically, sedation lasted longer in non-geriatric subjects (Fig. 3C) . For both age groups, sedation was significantly increased (i.e., lower maximum sum score for OAA/S) following the higher 5.0 mg USL261 dose (P b 0.05), though there were no significant differences between age groups at the same dose level ( Fig. 3D; supplemental Table 2) .
Trends similar to those for sum scores were observed with OAA/S composite scores. The lowest observed score of 2 ("Responds only after mild prodding or shaking") was seen in non-geriatric subjects only.
Psychomotor impairment: Digit Symbol Substitution Task
Psychomotor impairment with USL261 was more evident following the higher dose (Fig. 4) . Psychomotor effects occurred rapidly after dosing and returned to baseline within 1 to 4 h post-dose for both parameters ( Fig. 4A and C) . Mean baseline-adjusted DSST completion rate values were similar in both age groups within each dose, whereas mean baseline-adjusted percent correct values were decreased in geriatric subjects for the first 30-45 min post-dose (Fig. 4) .
Similar trends were observed with E max , with significantly more pronounced effects (i.e., lower values) following 5.0 mg USL261 compared with 2.5 mg USL261 (P b 0.01 for both completion rate and percent correct; Fig. 4B and D; supplemental Table 3 ). No significant differences were observed when comparing age groups; though slight numerical differences were observed for percent correct, completion rate differences were close to zero ( Fig. 4B and D; supplemental Table 3 ).
Median T effect for both DSST assessments was generally earlier for geriatric subjects at both USL261 doses (~17-32 min for geriatric, 40 min-2 h for non-geriatric), except for completion rate at the 5.0 mg dose (~21 min for both groups). Although non-geriatric subjects following 2.5 mg USL261 exhibited a median T effect of 2 h, this value does not appear to be representative of drug effect and was not used for comparative purposes because of the small E max magnitude, with a mean change from baseline of just −3.1%.
PK-PD relationship
It has previously been shown that a PK-PD relationship exists between plasma MDZ concentration and DSST performance [52] . In order to assess whether PK-PD relationships for MDZ differ with age, individual DSST E max values were plotted versus matched MDZ C max values for both age-groups. (As MDZ T max values and DSST T effect were similar, this suggests minimal hysteresis and that this E max versus C max comparison is appropriate.) Consistent with the literature, a PK-PD relationship was observed graphically, indicating more pronounced psychomotor impairment with increasing peak plasma MDZ concentrations (supplemental Fig. 1 ). The trend for DSST percent correct suggests a possible curvilinear, rather than linear, relationship between E max and C max , with sedation becoming more pronounced above 40 ng/mL (supplemental Fig. 1B) . No clear agerelated differences in the PK-PD relationship for either DSST parameter were observed.
Safety and tolerability
A similar percentage of geriatric (89%) and non-geriatric (83%) subjects across both doses had at least one TEAE during the study, though at each individual dose a higher percentage of geriatric subjects experienced ≥1 TEAE (Table 3) . TEAEs related to the nose, throat, and taste predominated, consistent with nasal administration.
Of 115 TEAEs, 105 were deemed related to study drug; all were of mild (109) or moderate (6) severity. Of the moderate TEAEs observed following both USL261 doses, three occurred in each age group, indicating TEAE severity did not worsen in the geriatric population.
One sedative/psychomotor TEAE (depressed level of consciousness) was reported in a geriatric subject following 2.5 mg USL261, but was mild, transient, and not present following 5.0 mg. There were no serious adverse events, and no subjects discontinued the study due to TEAEs.
Overall, vital signs and laboratory values remained within reference ranges; oxygen saturation percentages remained ≥90% in all patients, with the majority ≥ 95%. No additional safety-related findings were found.
Discussion
Following a single 5.0 mg dose of USL261, overall (AUC 0-∞ ) and maximum (C max ) plasma MDZ exposure were~45% and 20% higher, respectively, in geriatric versus non-geriatric subjects. Higher exposure to drug in geriatric subjects also was indicated by the pharmacokinetic data for the active metabolite, 1-OH-MDZ. Increased exposure to MDZ was secondary to slower clearance and longer t 1/2 values in geriatric subjects. This is consistent with observations for IV MDZ; for example, Abbreviations: 1-OH-MDZ, 1-hydroxymidazolam; AUC 0-∞ , area under the plasma concentration time-curve estimated from 0 to infinity; CI, confidence interval; CL/F, apparent total body clearance; C max , maximum plasma concentration; CV, coefficient of variation; GLSM, geometric least-squares mean; MDZ, midazolam; MR AUC 0-∞ , metabolite to parent molar ratio for AUC 0-∞ ; MR C max , metabolite to parent molar ratio for C max ; t 1/2 , terminal elimination half-life; T max , time to maximum plasma concentration; V z /F, volume of distribution. a n = 17 for AUC 0-∞ , t 1/2 , CL/F, and V z /F; n = 16 for MR AUC 0-∞ . b GLSM are calculated by exponentiating the least-squares means from the ANOVA.
the geriatric/non-geriatric ratios of geometric mean CL/F values observed in this study (2.5 mg: 0.77; 5.0 mg: 0.70) were similar to IV MDZ, with reported clearance ratios ranging from 0.56-0.75 [39, 40, 42] . Similarly, geriatric/non-geriatric ratios of mean t 1/2 values in this study (2.5 mg: 1.41; 5.0 mg: 1.32) were in the range reported in IV MDZ studies (1.12-3.08) [39, 40, 42, 46] . Observed similarities of USL261 to IV MDZ suggest USL261 PK differences in the geriatric population reflect a decrease in clearance rather than an increase in bioavailability. These results may help guide dosing recommendations in geriatric patients to determine what, if any, dose adjustments would be recommended for USL261. The PK similarity between USL261 and IV MDZ is attributed to similar bypass of first-pass metabolism, as has been suggested for IN drugs in general and IN MDZ specifically [24, 25] . This is supported by the low metabolite-to-parent molar AUC ratio (MR-AUC) for USL261, as high extraction ratio drugs such as MDZ exhibit a high MR-AUC when administered via routes susceptible to first-pass metabolism (i.e., oral). The MR-AUC values observed in this study (~0.17) were low in magnitude and more similar to those reported for IV MDZ (~0.12) compared with those of oral MDZ (ranging from 0.48 to 0.70) [26, 53] . This suggests that while 1-OH-MDZ is approximately equipotent to MDZ for sedative effects [54] , the metabolite did not appreciably contribute to observed pharmacodynamic effects.
Despite the increased MDZ exposure in the geriatric group, there were no significant differences in maximal sedation and psychomotor impairment mean scores between the age groups. This is noteworthy since sedation and psychomotor impairment were sensitive to MDZ exposure; PD effects were significantly more pronounced with 5.0 mg USL261 versus 2.5 mg and were observed shortly after drug administration with return to baseline generally within 4 h. While this study was not specifically designed to have power to detect a minimal statistically significant difference in PD parameters, the size of the trial was sufficient to detect a large difference in sedation and psychomotor impairment across groups with reasonable precision. The size of the 90% CI range supports this conclusion, and indicates that there was no clinically meaningful difference in sedation and psychomotor impairment between geriatric and non-geriatric subjects.
Geriatric subjects in this study were less impacted by MDZ in relation to non-geriatric subjects than geriatric subjects in previous studies [41, 44, 45, 55] ; for example, Albrecht et al. observed hypnotic and sedative effects in elderly subjects comparable to young adults after treating the elderly with MDZ IV infusions of approximately 35 mg, half the dose administered to young adults [44] . While it is hypothesized that this is due to the lower doses used in the current study (after adjusting for bioavailability) as compared to the other studies, the inter-study differences may be attributed in part to different study designs.
Both USL261 doses were well tolerated by both age groups. Subjects reported only mild-to-moderate adverse events and no subject discontinued the study because of TEAEs. The OAA/S composite scores show no excess of sedation (no composite score on the responsiveness domain of 1, "does not respond to mild prodding or shaking") for either group. In the U.S., the product label includes a boxed warning for IV MDZ stating that there is an association with "respiratory depression and respiratory arrest, especially when used for sedation in noncritical care settings." Vital signs stayed within normal ranges throughout the study and oxygen saturation levels also remained in accepted normal limits at the doses given here throughout the study.
One study limitation is that selected geriatric participants had no cardiovascular conditions; as elderly patients may present with such comorbidities [56] , the effect of IN MDZ on such individuals is unclear. These patients are likely to take medications that may affect MDZ metabolism and drug exposure. For example, CYP3A inhibitors-which decrease MDZ clearance-include high blood pressure and angina medications like diltiazem [57] and verapamil [58] , frequently taken by the elderly. Decreased MDZ clearance could result in greater PD effects and higher incidence of adverse events. In contrast, CYP3A inducers-including the anti-epileptic drugs (AEDs) phenobarbital and oxcarbazepine-increase MDZ clearance [59, 60] , which is expected to reduce PD effects. This is supported by previous phase 1 studies of USL261, where patients with epilepsy on concomitant AEDs had reduced PD effects versus healthy subjects [32] [33] [34] .
In conclusion, IN USL261 was rapidly absorbed following 2.5 and 5.0 mg doses, with enhanced PK and PD effects with the higher Fig. 4 . Baseline-adjusted DSST scores versus time and DSST E max values by dose and age group: trial completion rate (panels A and B) and percent correct (panels C and D). For both DSST assessments, lower scores indicate increased psychomotor impairment. In panels B and D, the hatched line represents the median value. The box represents the 25th and 75th percentiles (interquartile range, IQR) whereas the whiskers show the lowest and highest data points within 1.5 IQR of the lower and upper quartile, respectively. Open circles represent potential outliers (i.e., data points outside of 1.5 IQR).
Table 3
Incidence of TEAEs occurring in ≥2 subjects for each USL261 dose by age group. USL261 dose. Despite increased MDZ exposure in relatively healthy geriatric subjects, there were no significant PD differences between age groups; this suggests that PK differences may not translate to observable or clinically relevant changes in PD. Similar TEAE rates between cohorts suggest the magnitude of increased exposure in geriatric subjects may not negatively affect tolerability. These PK, PD, and safety/tolerability findings support continued USL261 development for the rescue treatment of patients with intermittent bouts of increased seizure activity in adults of all ages.
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